ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR24

Changes in CKD Prevalence in the United States Using the Age-Adapted CKD Classification System

Session Information

Category: CKD (Non-Dialysis)

  • 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Tio, Maria Clarissa, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Syed, Aliba, University of California Irvine, Irvine, California, United States
  • Streja, Elani, University of California Irvine, Irvine, California, United States
  • Talluri, Rajesh, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Obi, Yoshitsugu, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Shafi, Tariq, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Kalantar-Zadeh, Kamyar, University of California Irvine, Irvine, California, United States
Background

Current eGFR criteria for diagnosing CKD (eGFR<60 mL/min/1.73m2) do not take an individual’s age into consideration. An age-adapted CKD definition was recently proposed (JASN 2019). We determined the changes in CKD prevalence in the US, comparing the current KDIGO classification system (CKD-KDIGO) to an age-adapted CKD classification system (CKD-Age).

Methods

We analyzed data from the 2017-2020 National Health and Nutrition Examination Survey (NHANES; N=8,016). CKD-KDIGO was defined as having a CKD-EPI 2021 eGFR <60 mL/min/1.73m2 or ACR ≥30 mg/g. CKD-Age was defined as proposed: eGFR <75 mL/min/1.73m2 for ages 18 to <40 years, eGFR <60 mL/min/1.73m2 for ages 40 to 65 years, eGFR <45 mL/min/1.73m2 for ages >65 years, or ACR ≥30 mg/g. We used reclassification tables to determine changes in CKD prevalence.

Results

The US CKD population has a mean age of 60 years. Among the 31 million persons with CKD-KDIGO, 39.4% were 18 to <40 years old, 43.4% were 40-65 years, and 17.2% were >65 years. Median age is 71 years for CKD-KDIGO G3A, 76 years for G3B, 78 years for G4, and 63 years for G5. Using the CKD-Age classification, 5.2 million (16.7%) of those with CKD-KDIGO were reclassified to being CKD-free (Table 1). 1.2 million (0.6%) of those without CKD were reclassified to having CKD-Age and all of these individuals were 40-65 years old.

Conclusion

Age-based CKD classification may prevent overdiagnosis of CKD in older individuals and identify younger individuals with low eGFR at risk for kidney failure, allowing prioritization of care.

Funding

  • Other NIH Support